Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term protection and immunogenicity of recombinant HPV 16/18 bivalent (Escherichia coli) vaccine in adult women
CTR20231472Phase 4Active
- Sponsor
- Xiamen University
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human papillomavirus bivalent (types 16, 18) vaccine in human papillomavirus infection, cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VAIN), Cervical Cancer (CC), sponsored by Xiamen University. Started Apr 2021; status: active.
02
Drugs
recombinant human papillomavirus bivalent (types 16, 18) vaccine
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)vulvar intraepithelial neoplasia (VIN)vaginal intraepithelial neoplasia (VAIN)Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20231472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231472.